|
|
Volumn 8, Issue 4, 1989, Pages 431-440
|
|
Surrogate endpoints in clinical trials: Definition and operational criteria
|
|
Author keywords
Clinical trials; Disease prevention trials; Hazard rates; Surrogate endpoints; Therapeutic trials
|
|
Indexed keywords
CANCER THERAPY;
CLINICAL TRIAL;
DOSE TIME EFFECT RELATION;
HUMAN;
METHODOLOGY;
PREVENTION;
RISK ASSESSMENT;
SHORT SURVEY;
STATISTICS;
THEORETICAL STUDY;
BREAST NEOPLASMS;
CLINICAL TRIALS;
FEMALE;
HUMAN;
MASS SCREENING;
NEOPLASMS;
RESEARCH DESIGN;
STATISTICS;
SUPPORT, U.S. GOV'T, P.H.S.;
|
|
EID: 0024520844
PISSN: 02776715
EISSN: 10970258
Source Type: Journal
DOI: 10.1002/sim.4780080407 Document Type: Article |
|
Times cited : (1594)
|
|
References (6)
|
